Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Tempest Therapeutics, Inc. - Common Stock (NQ:TPST)

8.950 +0.700 (+8.48%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 9, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2,215,728
Open 10.98
Bid (Size) 8.990 (1)
Ask (Size) 9.000 (1)
Prev. Close 8.250
Today's Range 8.730 - 11.95
52wk Range 5.349 - 41.47
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Let's uncover which stocks are experiencing notable gaps during today's session.
The market is filled with gapping stocks in Monday's session. Let's discover which stocks are showing gap-ups and gap-downs. 
Via Chartmill
Why Circle Internet Group Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket
Via Benzinga

Performance

YTD
-19.8%
-19.8%
1 Month
+37.9%
+37.9%
3 Month
-12.7%
-12.7%
6 Month
-24.7%
-24.7%
1 Year
-78.3%
-78.3%

More News

Read More
Get insights into the top gainers and losers of Monday's pre-market session.
Via Chartmill
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Tempest Receives Orphan Drug Designation from the European Medicines Agency for Amezalpat for the Treatment of Patients with HCC
From Tempest Therapeutics
Via GlobeNewswire
Tempest Reports First Quarter 2025 Financial Results and Provides Business Update
From Tempest Therapeutics
Via GlobeNewswire
Tempest Presents New Amezalpat MOA Data Reinforcing Its Potential as Novel Cancer Treatment at the 2025 AACR Annual Meeting
From Tempest Therapeutics
Via GlobeNewswire
Tempest Receives Orphan Drug Designation from the FDA for TPST-1495 to Treat Patients with FAP
From Tempest Therapeutics
Via GlobeNewswire
Tempest Weighs M&A, Analyst Sees A "Broken Story" Despite Phase 2 Liver Cancer Study Success
Via Benzinga
Tempest Therapeutics Retail Chatter Explodes As Cancer Drug Developer Mulls Possible Merger
Via Stocktwits
Topics World Trade
Exposures Product Safety Tariff
Tempest Announces Plan to Explore Strategic Alternatives to Advance Promising Pipeline of Clinical Oncology Assets and Maximize Stockholder Value
From Tempest Therapeutics
Via GlobeNewswire
Monday's session: gap up and gap down stocks
Via Chartmill
Tempest Reports Year End 2024 Financial Results and Provides Business Update
From Tempest Therapeutics
Via GlobeNewswire
Tempest Announces Amezalpat Poster Presentation at the 2025 American Association for Cancer Research (AACR) Annual Meeting
From Tempest Therapeutics
Via GlobeNewswire
FDA Study May Proceed Notice Received for Phase 2 Trial of TPST-1495 for the Treatment of Familial Adenomatous Polyposis (FAP)
From Tempest Therapeutics
Via GlobeNewswire
Tuesday's after hours session: top gainers and losers
Via Chartmill
Tempest Granted Fast Track Designation from the U.S. Food and Drug Administration for Amezalpat to Treat Patients with Hepatocellular Carcinoma
From Tempest Therapeutics
Via GlobeNewswire
Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Tempest Therapeutics
Via GlobeNewswire
Tempest Receives Orphan Drug Designation from the U.S. Food and Drug Administration for Amezalpat to Treat Patients with Hepatocellular Carcinoma (HCC)
From Tempest Therapeutics
Via GlobeNewswire
Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Tempest Therapeutics
Via GlobeNewswire
Tempest to Participate in the Piper Sandler 36th Annual Healthcare Conference
From Tempest Therapeutics
Via GlobeNewswire
Tempest Reports Third Quarter 2024 Financial Results and Provides Business Update
From Tempest Therapeutics
Via GlobeNewswire
Tempest Receives FDA Study May Proceed for Pivotal Phase 3 Trial of Amezalpat Combination Therapy for the Treatment of First-Line Hepatocellular Carcinoma
From Tempest Therapeutics
Via GlobeNewswire
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Why Alphabet Shares Are Trading Higher By Around 6%; Here Are 20 Stocks Moving Premarket
Via Benzinga

Frequently Asked Questions

Is Tempest Therapeutics, Inc. - Common Stock publicly traded?
Yes, Tempest Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Tempest Therapeutics, Inc. - Common Stock trade on?
Tempest Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Tempest Therapeutics, Inc. - Common Stock?
The ticker symbol for Tempest Therapeutics, Inc. - Common Stock is TPST on the Nasdaq Stock Market
What is the current price of Tempest Therapeutics, Inc. - Common Stock?
The current price of Tempest Therapeutics, Inc. - Common Stock is 8.950
When was Tempest Therapeutics, Inc. - Common Stock last traded?
The last trade of Tempest Therapeutics, Inc. - Common Stock was at 06/09/25 04:00 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.